Centiva Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Centiva Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,292	Closed	-$51.6K	–	2186
2023 Q1	$51.6K	Buy	+12,292	New	+$63.8K	﹤0.01%	1379

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Centiva Capital's CTIC Position: Q2 2023 in Review

Centiva Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 12,292 shares — an estimated $51.6K sold.

Centiva Capital first reported a position in CTIC in Q1 2023 and held it in 1 quarter. The position peaked at $51.6K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Centiva Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 12,292 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $51.6K.
Centiva Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2023 and held it in 1 quarter.
Centiva Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $51.6K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.